Serendex Pharmaceuticals A/S - Product Pipeline Review - 2014

Published: Mar, 2014 | Pages: 23 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Serendex Pharmaceuticals A/S - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Serendex Pharmaceuticals A/S - Product Pipeline Review - 2014', provides an overview of the Serendex Pharmaceuticals A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Serendex Pharmaceuticals A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Serendex Pharmaceuticals A/S including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Serendex Pharmaceuticals A/S's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Serendex Pharmaceuticals A/S's pipeline products

Reasons to buy

- Evaluate Serendex Pharmaceuticals A/S's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Serendex Pharmaceuticals A/S in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Serendex Pharmaceuticals A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Serendex Pharmaceuticals A/S and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Serendex Pharmaceuticals A/S
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Serendex Pharmaceuticals A/S and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Serendex Pharmaceuticals A/S Snapshot 4
Serendex Pharmaceuticals A/S Overview 4
Key Information 4
Key Facts 4
Serendex Pharmaceuticals A/S - Research and Development Overview 5
Key Therapeutic Areas 5
Serendex Pharmaceuticals A/S - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Serendex Pharmaceuticals A/S - Pipeline Products Glance 10
Serendex Pharmaceuticals A/S - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Serendex Pharmaceuticals A/S - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Serendex Pharmaceuticals A/S - Drug Profiles 13
sargramostim 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
drotrecogin alfa (activated) 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
eptacog alfa 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
fosfomycin 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Serendex Pharmaceuticals A/S - Pipeline Analysis 17
Serendex Pharmaceuticals A/S - Pipeline Products by Target 17
Serendex Pharmaceuticals A/S - Pipeline Products by Route of Administration 18
Serendex Pharmaceuticals A/S - Pipeline Products by Molecule Type 19
Serendex Pharmaceuticals A/S - Pipeline Products by Mechanism of Action 20
Serendex Pharmaceuticals A/S - Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 23
Disclaimer 23

List of Tables
Serendex Pharmaceuticals A/S, Key Information 4
Serendex Pharmaceuticals A/S, Key Facts 4
Serendex Pharmaceuticals A/S - Pipeline by Indication, 2014 7
Serendex Pharmaceuticals A/S - Pipeline by Stage of Development, 2014 8
Serendex Pharmaceuticals A/S - Monotherapy Products in Pipeline, 2014 9
Serendex Pharmaceuticals A/S - Phase II, 2014 10
Serendex Pharmaceuticals A/S - Phase I, 2014 11
Serendex Pharmaceuticals A/S - Preclinical, 2014 12
Serendex Pharmaceuticals A/S - Pipeline by Target, 2014 17
Serendex Pharmaceuticals A/S - Pipeline by Route of Administration, 2014 18
Serendex Pharmaceuticals A/S - Pipeline by Molecule Type, 2014 19
Serendex Pharmaceuticals A/S - Pipeline Products by Mechanism of Action, 2014 20
Serendex Pharmaceuticals A/S, Subsidiaries 21